Issue 22, 2022

A sustainable nano drug delivery system for poorly soluble drug, glipizide: design, in vitro controlled release and kinetics

Abstract

The present work deals with the design of drug delivery systems based on 12-tungstophosphoric acid (TPA)-functionalized MCM-48 nanoparticles (TPA/nMCM-48), for poorly soluble drug GLP. Two DDSs, namely GLP loaded on TPA/nMCM-48 and capped by TPA, were designed and characterized by various techniques. An in vitro release study of GLP was carried out in simulated body fluid (pH-7.4, 37 °C) under stirring conditions followed by the evaluation of the release kinetics and mechanism. The release profiles of the designed DDSs were compared with the release profiles of a commercially available formulation (Glynase) and GLP/nMCM-48. The comparison study indicates that TPA acts better as a functionalizing agent rather than as a capping agent and when compared with the marketed formulation, GLP/TPA/nMCM-48 shows more controlled release of GLP with only 15% cytotoxicity.

Graphical abstract: A sustainable nano drug delivery system for poorly soluble drug, glipizide: design, in vitro controlled release and kinetics

Article information

Article type
Paper
Submitted
02 Jun 2022
Accepted
29 Aug 2022
First published
12 Sep 2022
This article is Open Access
Creative Commons BY license

Mater. Adv., 2022,3, 8220-8228

A sustainable nano drug delivery system for poorly soluble drug, glipizide: design, in vitro controlled release and kinetics

D. Dasgupta and A. Patel, Mater. Adv., 2022, 3, 8220 DOI: 10.1039/D2MA00627H

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements